Blue rose reveals true RNAi colours
Wednesday, 30 March, 2005
The CSIRO has revealed that part of the technology used to develop the blue rose -- unveiled last year by Japanese giant Suntory and its subsidiary, Melbourne company Florigene -- was an RNAi technique developed by CSIRO for gene replacement in plants.
In its first commercial application in plants, the CSIRO-developed RNAi technology was used to inactivate the gene encoding the enzyme dihydroflavonol reductase (DFR) in roses. The enzyme directs the synthesis of red pigments in the flower.
An RNAi molecule which hybridises with the rose DFR gene was used to inhibit the gene's expression. Scientists then inserted Florigene's patented iris DFR gene -- which makes a lot of blue pigment - plus the delphinidin gene from pansy, a gene missing in roses, to produce a blue rose.
The blue rose has yet to gain regulatory approval before it can be commercially grown and marketed.
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
